Varian and GenesisCare to Form Strategic Partnership for Cancer Care Research and Increased Access to Care

Varian (NYSE: VAR) and GenesisCare, a leading provider of cancer care treatment, today announced the signing of a memorandum of understanding (MoU) to form a strategic partnership for cancer care research and to increase access to advanced cancer care in Australia, the United Kingdom and Spain. The relationship is intended to cover up to a total of 70 Varian linear accelerators and Varian Eclipse(TM) treatment planning software as the preferred GenesisCare solution provider globally. It will also include support of skin cancer clinical trials utilizing Varian RapidArc technology and the development of software for the emerging field of theranostics.

Skin cancer is among the world’s most prevalent cancers, with an estimated 1.04 million cases diagnosed globally each year,1 and a major research focus at GenesisCare. With this partnership, GenesisCare will work closely with Varian to accelerate the application of Varian’s products and services to support advanced skin cancer management, and also launch new skin cancer trials.

The partnership will also focus on the emerging field of theranostics, also known as molecular targeted radiation. Theranostics uses nanoscience to unite diagnostic and therapeutic applications to form a single cancer fighting agent. Utilizing Varian’s expertise in image-guided medicine and GenesisCare’s experience in theranostics research and treatment delivery, Varian and GenesisCare will partner to develop image-guided treatment monitoring solutions in this evolving area.

“By forming this strategic partnership, we have the opportunity to combine Varian’s advanced treatment technology with GenesisCare’s ‘Service of the Future’ operating model to improve access to high quality cancer care and potentially produce better outcomes for patients,” said Dan Collins, Chief Executive Officer and founder, GenesisCare.

“We are excited to be partnering with GenesisCare on both increasing the access to care, while at the same time collaborating on potential future treatment solutions for skin cancer and theranostics,” said Dow Wilson, President and Chief Executive Officer, Varian. “This partnership represents another significant step towards achieving our vision of a world free from fear of cancer.”

Concurrently, GenesisCare placed an order for 10 linear accelerators in Australia, which Varian booked in its recently completed fourth quarter of fiscal year 2018. Installation of the first Varian Halycon(TM), TrueBeam(R) and Edge systems, as well as Eclipse, will begin in November 2018.

About Varian

Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world.

/Public Release.